Medlines
Medlines
Healthcare is changing at breakneck speed, and let's face it, staying informed is getting harder by the day. If only there were a way to get the industry news you need in less time than it takes to get prior auth approved. (Spoiler: There is.)

Every Friday, start your day with Dr. Will Flanary (aka Dr. Glaucomflecken), Dr. Alok Patel, Adam Rose, and Eva Johnson as they bring you the week's most important headlines across clinical care, health policy, groundbreaking publications, medical pop culture, and more. Presented with clear, unbiased, fact-first reporting made strictly for healthcare professionals, by healthcare professionals.

Prepare to wow your colleagues with how informed you are, all without risking another evening doom-scrolling through 5% actual news and 95% videos of, well, if you know you know. 

Medicine moves fast... So do we!
Nov. 13, 2026

The Lp(a) Letdown and Tumors After Gene Therapy

The Lp(a) Letdown and Tumors After Gene Therapy
Medlines
The Lp(a) Letdown and Tumors After Gene Therapy

Key Takeaways

  • Dr. Jennifer Lincoln and Eva Johnson break down the results of the Lp(a)HORIZON and ZEUS trials, highlighting why reducing a biomarker does not always translate to improved clinical outcomes.
  • Pelacarsen successfully lowered Lp(a) levels, but the trial ultimately showed no significant reduction in cardiovascular events.
  • The ZEUS trial evaluating ziltivekimab also fell flat, reminding clinicians that moving a risk marker is not the same as changing real-world patient outcomes.
  • The FDA is investigating a potential tumor risk following the administration of the SMA gene therapy Zolgensma, prompting closer evaluation of long-term patient monitoring.
  • This episode also touches on practical healthcare updates, including a plasma hack, AI-driven prior authorization insights, statin nudges, and an NFL star's neck injury recovery.

Friday, November 13, 2026

In today's episode, Dr. Jennifer Lincoln (@drjenniferlincoln) & Eva Johnson cover two large heart drug trials that lowered markers but not events. They break down Lp(a)HORIZON, which tested pelacarsen, and ZEUS, which tested ziltivekimab. They explain why moving a risk marker is not the same as changing outcomes. Plus: they also discuss an FDA investigation into tumors after the SMA gene therapy Zolgensma, what monitoring may mean for practice, an NFL star's scary neck injury, and more.

Coverage Timeline:

(00:00) This Week’s Headlines (01:44) Pelacarsen: Big Drop, No Benefit (03:03) ZEUS Falls Flat (05:24) Gene Therapy’s Tumor Risk (08:05) Plasma Hack, AI Prior Auth & Statin Nudges (09:45) Jack Campbell’s Recovery

Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com.

Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources

Medlines is a Human Content Production

Frequently Asked Questions

What did the Lp(a)HORIZON trial reveal about pelacarsen?

The Lp(a)HORIZON trial showed that while pelacarsen successfully achieved a big drop in Lp(a) levels, it did not translate into a reduction in clinical cardiovascular events.

Why did the ZEUS trial fall flat?

The ZEUS trial, which tested ziltivekimab, failed to improve patient outcomes despite targeting specific inflammatory risk markers, reinforcing the clinical lesson that moving a marker isn't the same as changing outcomes.

Why is the FDA investigating the gene therapy Zolgensma?

The FDA is investigating reports of tumors following the administration of the spinal muscular atrophy (SMA) gene therapy Zolgensma, which may impact future patient monitoring protocols.

Who hosts this episode of Medlines alongside Eva Johnson?

This episode is hosted by Eva Johnson and guest co-host Dr. Jennifer Lincoln, breaking down the week's top medical headlines.